Hrt Financial LP Crispr Therapeutics Ag Transaction History

Hrt Financial LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$60.67 - $89.12 $4.21 Million - $6.19 Million	69,429 New	69,429 $4.73 Million
Q2 2023 Aug 11, 2023	SELL	$43.47 - $67.77 $929,866 - $1.45 Million	-21,391 Reduced 60.28%	14,093 $791,000
Q1 2023 May 12, 2023	BUY	$41.0 - $56.12 $877,400 - $1.2 Million	21,400 Added 151.95%	35,484 $1.6 Million
Q4 2022 Feb 10, 2023	BUY	$39.19 - $65.67 $551,951 - $924,896	14,084 New	14,084 $572,000
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $11.2 Million - $15.9 Million	-101,731 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $9.2 Million - $14.8 Million	91,222 Added 868.04%	101,731 $16.5 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $1.16 Million - $2.21 Million	10,509 New	10,509 $1.28 Million
Q3 2020 Nov 13, 2020	SELL	$78.5 - $100.64 $295,631 - $379,010	-3,766 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $144,991 - $286,404	3,766 New	3,766 $276,000
Q1 2019 May 14, 2019	SELL	$28.02 - $40.87 $290,875 - $424,271	-10,381 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$22.73 - $42.34 $235,960 - $439,531	10,381 New	10,381 $296,000

486

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.39B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.